Navigation Links
PharmAthene's 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review
Date:7/9/2009

y human monoclonal antibody for the prevention and treatment of anthrax infection
  • Protexia(R) - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents
  • RypVax(TM) - a recombinant dual antigen vaccine for plague

  • For more information about PharmAthene, please visit www.PharmAthene.com.

    Statement on Cautionary Factors

    Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; or similar statements are forward-looking statements. PharmAthene disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, including without limitation our bid related to SparVax(TM) under the HHS Request for Proposals for an Anthrax Recombinant Protective Antigen (rPA) Vaccine for the Strategic National Stockpile, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the dev
    '/>"/>

    SOURCE PharmAthene, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related biology technology :

    1. KBI Biopharma Starts Cell Line Generation Process under Vendor Network Agreement for PER.C6(R)
    2. New Generation Biofuels Signs Letter of Intent with Instituto Costarricense de Electricidad (ICE) of Costa Rica
    3. A-Power Energy Generation Systems Ltd. Signs a Biomass-Based DG Contract with Sanmenxia New Energy Bio-Electricity Co., Ltd.
    4. Calvert Research Licenses Novel Technology to Treat Age Related Macular Degeneration from Tulane University
    5. Jatrophaworld Training 2009: 2nd Generation nonfood Biofuel crops Knowledge Platform
    6. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
    7. FDA Approves Boston Scientifics Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System
    8. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
    9. Nanosys Licenses Nanowire Technology to QuantuMDx Group for Next Generation Diagnostic and Sequencing Technologies
    10. City of Baltimore to Evaluate New Generation Biofuels for Use in Boiler Applications
    11. SeqWright Expands into the Genetically-Targeted Therapy Field by Partnering with PharmaGenoma to Provide Next-Generation Hair Loss Treatment Genetic Testing
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/13/2014)... and TAICHUNG, Taiwan (PRWEB) December 12, 2014 ... less rosy indicators in overall global economic growth, Eugene ... optics and photonics , said in a featured talk ... on 5 December at the National Chung Hsing University ... which is being integrated into future energy supplies and ...
    (Date:12/13/2014)... York, New York (PRWEB) December 13, 2014 ... of its global network and Cold Chain capabilities, and ... Control Tower in Paris, France, to serve Life Science ... new facility equipped with a controlled-ambient warehouse, will provide ... storage for vaccines and investigational drugs, patient-clinical specimens, API, ...
    (Date:12/13/2014)... , Dec. 12, 2014  Vaccinex Inc., ... discovery and development of therapeutic monoclonal antibodies ... announced publication of a manuscript entitled "SEMA4D ... remyelination in neurodegenerative disease" in the January ... Disease*.  The publication highlights an important role ...
    (Date:12/12/2014)... NY (PRWEB) December 11, 2014 Graphite ... bushing materials for pumps and process equipment, has appointed ... United States and Ontario, Canada. Staller holds a B.S. ... experience in the industrial market place, much of it ... based out of his Michigan office. , “We ...
    Breaking Biology Technology:Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 2Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 3Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 5Quick Opens Office in France to Serve Life Science Community In France and Neighboring French-Speaking Countries 2Vaccinex announces publication of preclinical studies with an anti-SEMA4D antibody in animal models of neuroinflammatory and demyelinating disease 2Kirk Staller Joins Graphite Metallizing Corporation 2
    ... Pharmacyclics, Inc.,(Nasdaq: PCYC ) today announced that ... the company has regained compliance with Marketplace Rule,4450(a)(5) (the ... bid,price of the Company,s common stock. Nasdaq had previously ... stock had failed to maintain a,minimum bid price of ...
    ... 29 /Xinhua-PRNewswire-FirstCall/ -- Renhuang,Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" ... Republic of China ("PRC"),today reported solid financial results for ... Fourth Quarter Fiscal 2007 Highlights, -- ... the fourth quarter of 2006, ...
    ... Verizon Keynote at Leading Pharmaceutical Communication Event, Where Executives Gather to ... for Pharmaceutical, Biotech and Medical Technology ... ... pleased to announce the participation of two keynote speakers from the,U.S. Food ...
    Cached Biology Technology:Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 2Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 3Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 4Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 5Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 6Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 7Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 8Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 9FDA's Chief of Staff, Susan Winckler and Peter Thonis, Chief Communications 2FDA's Chief of Staff, Susan Winckler and Peter Thonis, Chief Communications 3
    (Date:12/10/2014)... Forest Baptist Medical Center today announced plans for a ... Funding for this $50 million capital project is part ... launched next summer. The medical education ... R.J. Reynolds Tobacco Company complex, adjacent to 525@vine in ... plans to be ready to welcome medical students in ...
    (Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a ... $2.3 million in Series A1 funding led by UK-based ... also participated in the investment round. "We ... healthcare community adopts next-generation sequencing and seeks new approaches ... Reid Robison , MD MBA, and CEO of ...
    (Date:11/21/2014)... , Nov. 19, 2014  Earlier this year ... York College, and one of the most prolific inventors ... that are transmitted from Smartphones to third party agencies. ... and has one of the earliest known patents in ... usage in the military, child care, elder care and ...
    Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
    ... in Antarctica, funded by the National Science Foundation (NSF), have ... and greenhouse gases in the atmosphere that extends back 68,000 ... the ice containing the record is known as the WAIS ... the core contain uniquely detailed information on past environmental conditions ...
    ... molds and fungi, bacteria and viruses. To kill them off ... are, as a rule, treated chemically. However, recently this method ... have been withdrawn, but the granting of new permits has ... E. coli infection which was caused by beansprout ...
    ... ARBORMany medically minded researchers are in hot pursuit of ... and the interiors of cells, but University of Michigan ... to overcome: escaping the bloodstream. Drug delivery ... medicines could be more effective at lower doses and ...
    Cached Biology News:Antarctic ice core contains unrivaled detail of past climate 2Antarctic ice core contains unrivaled detail of past climate 3Healthy seeds -- treated environmentally friendly 2Healthy seeds -- treated environmentally friendly 3Achilles heel: Popular drug-carrying nanoparticles get trapped in bloodstream 2Achilles heel: Popular drug-carrying nanoparticles get trapped in bloodstream 3
    Recombinant Cat Interferon Alpha Activity: 2.7 x 10 7 u/mg...
    ... in the forefront of chemical peptide synthesis ... synthesis in solution. , Our Functional Peptides ... HPLC at no extra cost, thus we ... quality standard. , Our team of expert ...
    ... The RapidStak is a fast ... its class. Its high capacity ... and more confident walk away time ... and ease of set-up make for ...
    ... Electron RapidStak provides valuable walk-away time and ... buffer nest technology for parallel processing of ... fast, reliable automation for any laboratory in ... The RapidStak can be set-up within minutes ...
    Biology Products: